Ascendis Pharma Reports First Quarter 2026 Financial Results

- Q1 2026 revenue of €197 million for YORVIPATH ®   and €44 million for SKYTROFA ® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL ® enrollments since early April U.S. commercial launch - Entered into agreement to sell Rare Pediatric